Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 2—February 2022
Research

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Jennifer KertesComments to Author , Sharon Baruch Gez, Yaki Saciuk, Lia Supino-Rosin, Naama Shamir Stein, Miri Mizrahi-Reuveni, and Anat E. Zohar
Author affiliation: Maccabi HealthCare Services, Tel Aviv‒Jaffa Israel

Main Article

Table 3

Demographic and health characteristics of population vaccinated against coronavirus disease, by PCR test status, Maccabi Healthcare Services, Israel, January‒July 2021

Characteristic No. (%) not tested, n = 79,404 No. (%) tested, n = 5,141
Sex
M 33,871 (42.7) 2,128 (41.4)
F 45,533 (57.3) 3,013 (58.6)
Age group, y
<18 21,563 (27.2) 937 (18.2)
18–44 37,470 (47.2) 2,338 (45.5)
45–59 13,553 (17.1) 1,090 (21.2)
60–74 5,672 (7.1) 657 (12.8)
>75 1,146 (1.4) 119 (2.3)
Socioeconomic status
Low 10,744 (13.5) 1,339 (26.0)
Middle 36,358 (45.8) 1,234 (24.0)
High 32,302 (40.7) 2,568 (50.0)
Heart disease
No 78,105 (98.4) 5,021 (97.7)
Yes 1,299 (1.6) 120 (2.3)
Diabetes
No 76,320 (96.1) 4,903 (95.4)
Yes 3,084 (3.9) 238 (4.6)
Hypertension
No 73,063 (92.0) 4,524 (88.0)
Yes 6,341 (8.0) 617 (12.0)
Chronic kidney disease
No 78,058 (98.3) 5,012 (97.5)
Yes 1,346 (1.7) 129 (2.5)
Immunosuppressive disorder
No 78,193 (98.5) 5,010 (97.5)
Yes 1,211 (1.5) 131 (2.5)

Main Article

Page created: November 16, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external